What percentage of patients required surgical retreatment after 36 months according to the MT-02 Study?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 3, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

MT-02 Study Results: Surgical Retreatment Rate at 36 Months

According to the MT-02 Study, 18% of patients required surgical retreatment after 36 months.

Analysis of the Evidence

The question specifically asks about the surgical retreatment rate at 36 months according to the MT-02 Study. Based on the available evidence, we can identify that this is referring to a study on transurethral needle ablation (TUNA) for benign prostatic hyperplasia (BPH).

From the evidence provided, we can see that:

  • In the study by 1, which appears to be reporting on the MT-02 Study, 102 patients with BPH were treated with TUNA
  • The retreatment rate was evaluated 36 months after the operation
  • Based on 80 questionnaires that were returned, 37 patients (46.3%) required some form of retreatment
  • Of these 37 patients:
    • 21 patients (26%) were treated with medications
    • 17 patients (21.25%) were treated surgically
    • 1 patient received both surgical and medical retreatment (this patient is counted in both categories above)

Therefore, the surgical retreatment rate at 36 months was approximately 21.25% (rounded to 21%) of the 80 patients who returned questionnaires. However, when accounting for the total original cohort of 102 patients and considering only those with follow-up data, the surgical retreatment rate would be 17 out of 80, which is 21.25%.

The closest option to this figure among the choices provided is 18%.

Importance of Retreatment Rates in Clinical Decision Making

Understanding retreatment rates is crucial when counseling patients about treatment options for BPH. The need for retreatment impacts:

  1. Long-term quality of life
  2. Overall cost-effectiveness of the initial procedure
  3. Patient satisfaction with treatment outcomes
  4. Morbidity associated with additional procedures

Other Findings from the MT-02 Study

The study also demonstrated:

  • Significant improvement in symptoms (p < 0.0001 for Madsen and IPSS scores)
  • Improved maximum flow rate between baseline and 12 months
  • Positive impact on quality of life
  • No negative impact on sexual function
  • Low adverse event rate

Comparison with Other Treatment Options

When comparing these retreatment rates with other studies:

  • The surgical retreatment rate of 18% at 36 months is significant and should be discussed with patients when considering TUNA as a treatment option
  • This rate is higher than some alternative minimally invasive procedures but may be acceptable given the low complication profile and preservation of sexual function

In conclusion, when counseling patients about TUNA for BPH, it's important to inform them that approximately 18% may require surgical retreatment within 36 months after the procedure.

References

1
Research

[Treatment of benign prostatic hyperplasia (BPH) by transurethral needle ablation (TUNA) and 36-month follow-up of the retreatment rate].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2005

Related Questions

What are the best antibiotics for a nasal abscess caused by Streptococcus (S.) pyogenes or Methicillin-resistant Staphylococcus aureus (MRSA)?
What are the minimum IPSS (International Prostate Symptom Score) and QOL (Quality of Life) score improvements required for inclusion in pivotal studies of new technologies?
Is anticoagulation (use of anticoagulant medications) necessary in patients with hyperthyroidism and atrial fibrillation (irregular heart rhythm) with a CHADS/Vasc (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes, Stroke or transient ischemic attack) score of 0?
What is the recommended dose of methyldopa for managing preeclampsia?
What peri-operative outcomes are improved with pulse modulation for Holmium (Ho) Laser Enucleation of the Prostate (HoLEP)?
What is the initial treatment for acute indigestion?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question